Literature DB >> 11770241

Management of dengue fever in ICU.

A Soni1, K Chugh, A Sachdev, D Gupta.   

Abstract

Dengue virus infection can cause a wide spectrum of illness. Thrombocytopenia with concurrent haemoconcentration differentiates dengue haemorrhagic fever from classical dengue fever. Only cases with shock or unstable vitals signs need admission in the pediatric intensive care. The management is essentially supportive and symptomatic. The key to success is frequent monitoring and changing strategies. A rise in hematocrit of 20% along with a continuing drop in platelet count is an important indicator for the onset of shock. Patients in grade I and II should be closely monitored for signs of shock. The management of dengue shock syndrome (grade III and IV) is a medical emergency needing prompt and adequate fluid replacement for the rapid and massive plasma losses through increased capillary permeability. Early and effective replacement of plasma losses with plasma expanders or fluid and electrolyte solutions results in a favourable outcome in most cases. The ideal fluid management should include both cystalloids and colloids (including albumin). Cystalloids are given as boluses as rapidly as possible, and as many as 2 to 3 boluses may be needed in profound shock. Colloidal fluids are indicated in patients with massive plasma leakage and in whom a large volume of cystalloids has been given. Frequent recording of vital signs and determinations of haematocrit are important in evaluating the results of treatment. Apart from correction of electrolyte and metabolic disturbances, oxygen is mandatory in all patients of shock. Some patients develop DIC and need supportive therapy with blood products (blood, FFP and platelet transfusions). Polyserositis, in the form of pleural effusion and ascitis, are common in cases of dengue shock syndrome, and if possible, drainage should be avoided as it can lead to severe hemorrhages and sudden circulatory collapse. The prognosis depends mainly on the early recognition and treatment of shock.

Entities:  

Mesh:

Year:  2001        PMID: 11770241     DOI: 10.1007/bf02722356

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  11 in total

Review 1.  Dengue viral infection.

Authors:  Y K Sarin; S Singh; T Singh
Journal:  Indian Pediatr       Date:  1998-02       Impact factor: 1.411

2.  Dengue haemorrhagic fever and shock syndrome.

Authors:  J N Pande; S K Kabra
Journal:  Natl Med J India       Date:  1996 Nov-Dec       Impact factor: 0.537

3.  Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981.

Authors:  G P Kouri; M G Guzmán; J R Bravo; C Triana
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

4.  Disseminated intravascular coagulation in dengue haemorrhagic fever.

Authors:  T Srichaikul
Journal:  Southeast Asian J Trop Med Public Health       Date:  1987-09       Impact factor: 0.267

5.  An epidemic of dengue hemorrhagic fever and dengue shock syndrome in children in Delhi.

Authors:  A Aggarwal; J Chandra; S Aneja; A K Patwari; A K Dutta
Journal:  Indian Pediatr       Date:  1998-08       Impact factor: 1.411

6.  Failure of carbazochrome sodium sulfonate (AC-17) to prevent dengue vascular permeability or shock: a randomized, controlled trial.

Authors:  S Tassniyom; S Vasanawathana; T Dhiensiri; A Nisalak; A Chirawatkul
Journal:  J Pediatr       Date:  1997-10       Impact factor: 4.406

7.  Clinical manifestations of dengue haemorrhagic fever in children in Bandung, Indonesia.

Authors:  A Chairulfatah; D Setiabudi; A Ridad; R Colebunders
Journal:  Ann Soc Belg Med Trop       Date:  1995-12

8.  Failure of hydrocortisone to affect outcome in dengue shock syndrome.

Authors:  W Talogo; A Asrin; B Isnuhandojo; A Sahudi
Journal:  Pediatrics       Date:  1982-01       Impact factor: 7.124

9.  An epidemic of dengue haemorrhagic fever & dengue shock syndrome in & around Vellore.

Authors:  T Cherian; E Ponnuraj; T Kuruvilla; C Kirubakaran; T J John; P Raghupathy
Journal:  Indian J Med Res       Date:  1994-08       Impact factor: 2.375

Review 10.  Failure of high-dose methylprednisolone in established dengue shock syndrome: a placebo-controlled, double-blind study.

Authors:  S Tassniyom; S Vasanawathana; A Chirawatkul; S Rojanasuphot
Journal:  Pediatrics       Date:  1993-07       Impact factor: 7.124

View more
  6 in total

Review 1.  Fight against dengue in India: progresses and challenges.

Authors:  Bhavna Gupta; B P Niranjan Reddy
Journal:  Parasitol Res       Date:  2013-02-28       Impact factor: 2.289

Review 2.  Dengue viral infections.

Authors:  G N Malavige; S Fernando; D J Fernando; S L Seneviratne
Journal:  Postgrad Med J       Date:  2004-10       Impact factor: 2.401

Review 3.  Integrated view of molecular diagnosis and prognosis of dengue viral infection: future prospect of exosomes biomarkers.

Authors:  Rashmi Rana; Ravi Kant; Dinesh Kaul; Anil Sachdev; Nirmal Kumar Ganguly
Journal:  Mol Cell Biochem       Date:  2022-01-21       Impact factor: 3.396

4.  The outcomes of patients with severe dengue admitted to intensive care units.

Authors:  Chin-Ming Chen; Khee-Siang Chan; Wen-Liang Yu; Kuo-Chen Cheng; Hui-Chun Chao; Chiu-Yin Yeh; Chih-Cheng Lai
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 5.  Global distribution of infectious diseases requiring intensive care.

Authors:  Raul E Istúriz; Jaime Torres; José Besso
Journal:  Crit Care Clin       Date:  2006-07       Impact factor: 3.598

6.  Furosemide infusion in children with dengue fever and hypoxemia.

Authors:  K R Bharath Kumar Reddy; G V Basavaraja
Journal:  Indian Pediatr       Date:  2014-04       Impact factor: 1.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.